Patents Examined by Christine J. Saoud
  • Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
    Patent number: 11248031
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 15, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Paul E. Morin, Daniel Cohen, Ranjan Mukherjee, Timothy P. Reilly, Rose C. Christian, Dasa Lipovsek, Ray Camphausen, John Krupinski
  • Neuregulin based methods for treating heart failure
    Patent number: 11246909
    Abstract: The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 15, 2022
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Antigen binding proteins that bind to a complex comprising ?-Klotho and an FGF receptor
    Patent number: 11248052
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing ?-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ?-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: February 15, 2022
    Assignee: AMGEN INC.
    Inventors: Yang Li, Jennitte LeAnn Stevens, Chadwick Terence King, Ian Nevin Foltz, Gunasekaran Kannan, Junming Yie, Shaw-Fen Sylvia Hu
  • Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
    Patent number: 11241481
    Abstract: Provided herein are methods of modulating bile acid homeostasis or treating a bile-acid related or associated disorder, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), in combination with agents effective in modulating bile acid homeostasis or treating a bile-acid related or associated disorder.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: February 8, 2022
    Assignee: NGM BIOPHARMACEUTICALS, INC.
    Inventors: Lei Ling, Hui Tian
  • Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
    Patent number: 11235031
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: February 1, 2022
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Human monoclonal antibodies specific for FLT3 and uses thereof
    Patent number: 11236171
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: February 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien, Haiying Qin
  • FGF21 variants
    Patent number: 11230582
    Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 25, 2022
    Assignee: SANOFI
    Inventors: Mark Sommerfeld, Thomas Langer, Oliver Boscheinen, Matthias Dreyer, Werner Dittrich, Paul Habermann
  • Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
    Patent number: 11224634
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: January 18, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Treatment for age-related macular degeneration (AMD) and pathogenic ocular neovascularization
    Patent number: 11209444
    Abstract: The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: December 28, 2021
    Assignees: VEGENICS PTY LIMITED, THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
    Inventors: Megan E. Baldwin, Kameran Lashkari, Jie Ma
  • Methods for treating hypophosphatemic disorders
    Patent number: 11202822
    Abstract: The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: December 21, 2021
    Assignees: Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd.
    Inventors: Emil D. Kakkis, Javier San Martin, Tomohiro Sudo
  • Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
    Patent number: 11185570
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: November 30, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Extended release of neuregulin for treating heart failure
    Patent number: 11179323
    Abstract: The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: November 23, 2021
    Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.
    Inventor: Mingdong Zhou
  • Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
    Patent number: 11179440
    Abstract: A fusion protein containing a biologically active protein and an FGF21 mutant protein, a pharmaceutical composition containing the fusion protein, and their uses are disclosed. The fusion protein and the pharmaceutical composition are effective in treating a liver disease including hepatitis, hepatic fibrosis, and hepatic cirrhosis. The fusion protein has effects of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: November 23, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Han Na Hong, Jun Hwan Kim, Hyun Ho Choi, Dohoon Kim, Taewang Kim, Se Woong Oh, Moo Young Song, Jong Gyun Kim
  • Methods of treating an IGFBP-3R expressing cancer using anti-IGFBP-3R antibodies
    Patent number: 11179451
    Abstract: Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and/or survival by measuring the level of IGFBP-3R in tumor tissue are provided.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 23, 2021
    Assignee: Virginia Commonwealth University
    Inventors: Youngman Oh, Qing Cai
  • Nav1.9 target polypeptide, antibody and antibody fragment combined with same, and related pharmaceutical composition
    Patent number: 11174312
    Abstract: Provided is an antibody or a fragment thereof, which can be specifically bound to an S3-4 ring of a voltage sensor paddle of a domain III of voltage-gated sodium channel Nav1.9 ? sub-unit, and is able to inactivate a voltage sensor valve to keep sodium ions from entering nerve cells normally. Also provided is an epitope polypeptide specifically bound to the antibody or the fragment thereof, a pharmaceutical composition comprising the antibody or the fragment thereof, and a use of the antibody or the fragment thereof in preparing a drug for treating and diseases related to pains.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 16, 2021
    Assignee: POPULAS BIOPHARMACEUTICAL (WUHAN) LIMITED
    Inventor: Daichang Yang
  • Method of treating Rett Syndrome (RTT) with ghrelin
    Patent number: 11154592
    Abstract: A method of treating Rett Syndrome (RTT) comprising administering ghrelin to a subject in need thereof.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: October 26, 2021
    Assignee: KURUME UNIVERSITY
    Inventors: Toyojiro Matsuishi, Masayasu Kojima, Kotaro Yuge, Munetsugu Hara, Yushiro Yamashita
  • Anti-TREM-1 antibodies and uses thereof
    Patent number: 11155618
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 26, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • vNAR antibody which binds VEGF for use in dogs or cats
    Patent number: 11155612
    Abstract: The present invention relates to a novel vNAR protein of SEQ ID NO:1 capable of inhibiting the activity of VEGF in carnivorous mammals of the Canis and Felis genera, thereby inhibiting solid tumors growth of both genres.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 26, 2021
    Inventors: Alexei Fedorovish Licea Navarro, Dalia Vanessa Millán Gómez, Liliana Noemi Sánchez Campos, Carolina Elosua Portugal, Jorge Fernando Paniagua Solís, Salvador Dueñas Espinoza
  • Dual PDGF/VEGF antagonists
    Patent number: 11155610
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 26, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • Patient-specific biomarkers of invasion in inflammatory bowel disease
    Patent number: 11150237
    Abstract: The present invention provides methods of detecting increased carcinoembryonic antigen-related cell adhesion molecule (CEACAM) protein expression in a biological sample from a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene. The invention also provides methods of treating or preventing inflammatory bowel disease (IBD) in a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 19, 2021
    Assignee: The Regents of the University of California
    Inventor: Declan McCole